Navigation Links
S*BIO to Develop New JAK-2 Inhibitor for Treatment of Myeloproliferative Disorders and Hematological Malignancies
Date:9/10/2007

SINGAPORE, Sept. 11 /PRNewswire/ -- S*BIO Pte Ltd today announced the development of a novel and proprietary orally-administered compound, SB1518, for the treatment of myeloproliferative disorders (MPD) and certain hematological malignancies. MPD is believed to be caused by a specific mutation (V617F) of JAK2 and is a closely related group of hematological malignancies in which the bone marrow develops and functions abnormally. MPD is characterised by an excess of blood cells and the three main disorders include polycythemia vera (excess red blood cell mass), essential thrombocythemia (excess blood platelets) and myelofibrosis. S*BIO is a privately-held biotech company focusing on the research and clinical development of novel targeted small molecule drugs for the treatment of cancer.

SB1518 is a small molecule JAK2-selective kinase inhibitor. It has high potency against both the wild type JAK2 kinase and the JAK2 kinase with the activating V617F mutation which is found in high frequencies among three types of MPD and in some leukemias. By targeting the JAK2 activating mutation, SB1518 has the potential to interfere with a key mechanism driving the progress of MPD and other diseases.

"SB1518 has demonstrated excellent anti-proliferative and anti-tumor activity, combined with very good tolerability in relevant in vitro and in vivo models. SB1518 will address an important unmet medical need due to the lack of specific and effective long-term medical treatment for patients with MPD," said Dr. Jan-Anders Karlsson, CEO of S*BIO. "This promising new compound is our second success in the last twelve months and represents an important step in building S*BIO's strong pipeline of proprietary, targeted anti-cancer compounds."

In addition to SB1518, S*BIO has a robust pipeline including SB939, the company's lead histone deacetylase (HDAC) inhibitor which is currently in Phase 1 clinical trials. S*BIO's target-driven approach to innovative small molecule
'/>"/>

SOURCE S*BIO Pte Ltd
Copyright©2007 PR Newswire.
All rights reserved

4

GOOD

Page: 1 2

Related medicine technology :

1. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
2. Positive Clinical Results for DG041 Lead Product Development Highlights at deCODE R&D Event
3. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
4. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
5. Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule, Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for Clinical Development in Chronic Hepatitis C Virus Infection
6. Ambrilia Highlights Encouraging Data for its HIV Integrase Inhibitor Program and Recent Developments at Annual Meeting
7. Can-Fite Proceeds with Development of Third Drug; Progress in Development of CF502 Will Be Presented at the Annual European Congress of Rheumatology
8. CuraGen Presents Update on Clinical Development Program for Belinostat
9. Preclinical Study Finds Protease Inhibitor-Resistant HIV May Have Reduced Potential to Develop Resistance to Panacos Bevirimat
10. New Critical Path Report Highlights Research Needed to Foster Generic Drug Development
11. Staphylococcus aureus vaccine development on track ? safe and immunogenic in Phase I clinicaltrials

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2009)...prevent illnesses caused by subtypes A and B influ...Newswire-USNewswire/ -- The U.S. Food and Drug Adm... 18 years and older to prevent disease caused by i...ttp://www.newscom.com/cgi-bin/prnh/20090824/FDALOG...es and Diagnostics in Siena, Italy, was approved u...
(Date:11/26/2009)...Africa, Nov. 26 The 2009 Frost &am... in the Generic Pharmaceutical Market is presented...: http://www.newscom.com/cgi-bin/prnh/20081117/FS...e following criteria were used to benchmark Cipla ...th strategy and implementation, degree of innovati...
(Date:11/25/2009)...25 Hologic, Inc. (Hologi...loper, manufacturer and supplier of premium diagno...ts dedicated to serving the healthcare needs of wo...al Society of North America (RSNA) at McCormick Pl...09 to highlight our new SecurView(®) DX multi...
Breaking Medicine Technology:FDA Approves Agriflu Seasonal Influenza Vaccine 2Frost & Sullivan Award Underlines Cipla Medpro's Status as Company of the Year in the South African Generic Pharmaceutical Market 2Frost & Sullivan Award Underlines Cipla Medpro's Status as Company of the Year in the South African Generic Pharmaceutical Market 3Frost & Sullivan Award Underlines Cipla Medpro's Status as Company of the Year in the South African Generic Pharmaceutical Market 4New Hologic SecurView(R) DX Diagnostic Workstation Software Streamlines Workflow, Improves Radiologist Productivity 2New Hologic SecurView(R) DX Diagnostic Workstation Software Streamlines Workflow, Improves Radiologist Productivity 3New Hologic SecurView(R) DX Diagnostic Workstation Software Streamlines Workflow, Improves Radiologist Productivity 4Most Parents Worried About Bullying in U S High Schools 56990 1Most Parents Worried About Bullying in U S High Schools 56990 2Toshos Satisfaction With Health Robotics Steers the Japanese Pharmacy Automation Leader to Renew and to Expand its I V Automation Strategic Partnersh 56987 1Toshos Satisfaction With Health Robotics Steers the Japanese Pharmacy Automation Leader to Renew and to Expand its I V Automation Strategic Partnersh 56987 2Toshos Satisfaction With Health Robotics Steers the Japanese Pharmacy Automation Leader to Renew and to Expand its I V Automation Strategic Partnersh 56987 3Trius Torezolid Antibiotic for the Treatment of Severe Skin Infections Featured at ICAAC Meeting 4979 1Trius Torezolid Antibiotic for the Treatment of Severe Skin Infections Featured at ICAAC Meeting 4979 2Trius Torezolid Antibiotic for the Treatment of Severe Skin Infections Featured at ICAAC Meeting 4979 3
...WIRE)--Mar 7, 2007 - Gemin X,announced today that ...urnal Blood demonstrated that its lead compound, G...onses against,patient-derived multiple myeloma tum...oma effects when used as a combination therapy.,GX...o inhibit all,relevant members of the Bcl-2 protei...
...at the American College of,Cardiology,s Scientific...ewswire-FirstCall/ -- CV,Therapeutics, Inc. announ...the MERLIN TIMI-36 study of ranolazine shows there...atients on ranolazine.,The study did not meet the ...e company,s special protocol assessment,agreement ...
Other Medicine Technology:Gemin X Announces Publication of Preclinical Data of GX15-070 in,Multiple Myeloma in Blood 2CV Therapeutics Announces Topline MERLIN TIMI-36 Results 2CV Therapeutics Announces Topline MERLIN TIMI-36 Results 3
(Date:11/29/2009)...oosts urine production, experts say , ,...ke up during the night to urinate shouldn,t automa... breathing-related sleep disorder, could be the ca...ation, or nocturia, is comparable to loud snoring ...r in which soft tissue in the throat blocks the fl...
(Date:11/28/2009)...ider change after 30-minute psychosocial intervent...althDay News) -- A program that gets persistent dr... dangerous behavior may lead to significant and lo...he new study included 184 men and women with two o...e randomly assigned to one of two interventions. T...
(Date:11/27/2009)...plikins Ltd. today issued its latest biochemical a...that the lethality of the virus has dropped from i...nt outbreak in the spring of 2009 to resting non-e...N1 infectivity count, however, remains increased. ... 27, 2009 -- Biotech firm Replikins Ltd., which ha...
(Date:11/27/2009)...7 Shamir Optical Industr...ovider of innovative products and technology to th... board of directors had declared a dividend distri...pproximately NIS 37.62 million based on the Novemb...pproximately US$ 0.609 (approximately NIS 2.3 base...
(Date:11/27/2009)...rade; announced today that Spectrum Health (Grand ...prise orthopedic templating solution and its Traum... (PRWEB) November 27, 2009 -- Voyant Health...d Rapids, Michigan) has licensed its TraumaCad Ent...umaCad Extend workflow solution, to allow its orth...
Breaking Medicine News(10 mins):Health News:Sleep Apnea May Cause Nighttime Urination 2Health News:Sleep Apnea May Cause Nighttime Urination 3Health News:Drunk Drivers May Respond to Brief Motivational Interview 2Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 2Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 3Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 4Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 5Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 2Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 3Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 3
...ing to many studies pertaining to dental health a ...avities and is causing discoloured teeth.// T...nted at the American Association for Dental Resear...ch followed children from birth, starting in 1991-...
...han is considering of imposing a ban on the sale o...th of the children badly. With hot days round the ...pting for the chilled drinks. "The consumption...ted drinks in government-run schools," Ghanshyam T...
...in the blood thinner is not widely prescribed by t...k of stroke// and patients with abnormal heart rhy...ties. But the risk rates among them are the highes...study results were published in the journal Stroke...
...Health Organization and UNICEF conducted an intern...curring due to measles//. The results have proved ...% reduction. The global immunization drive was res...n estimated 454 000 by the end of 2004. Sub-Sahara...
Health products in Germany has grown in leaps and bounds as more and more health conscious Germans are willing to spend lavishly, be it for wellness//, sport, vitality or anti-ageing. The present tre
... feticide has become a common feature in the hill ...cides are carried out every year on an average//, ...the country. The shocking factor is that despite s...ale feticides every year, taking its gender ratio ...
Other Medicine News:Health News:Warfarin the Not So Popular Drug for Stroke 2Health News:Female Ratio Drops Alarmingly In Himachal Due To Feticides 2
Hudson Cranial Drill
Michele Vertebral Biopsy Trephine
Greenberg Universal Retractor Case
Greenberg Secondary Bar
Medicine Products: